Pay in 4 interest-free payments of $5.04 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
While the first drug in this class, exenatide (Byetta), was approved by the FDA in 2005, more recent drugs like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) outperform the older drugs in the class and other anti-obesity medications
These options may give people more choices and make treatment easier to fit into daily life in ways that feel more manageable and realistic
Gastrointestinal side effects may lead to treatment discontinuation in some patients, though severe cases remain rare and can be mitigated with appropriate monitoring (62)
CrossRef Quality of Gadoxetate-enhanced MRI versus US during Hepatocellular Carcinoma Screening in Participants with Cirrhosis Sara Lewis, Benjamin Wildman-Tobriner, Jordan Cuevas, Sergio Calle, Ian Bolger, Katherine Wang, Himanshu Joshi, Lori Mankowski Gettle, Ju Dong Yang, Ji Hye Min, Claude B
US$ 21.62
US$ 24.51
US$ 23.69
US$ 26.06
US$ 20.45
